In the Spotlight...

Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer

Using pancreatic tumor models with high and low TILs, Sanctis and Dusi et al. demonstrated the role of CLDN18 in regulating host tumor immunity. CLDN18 expression supported T cell infiltration and imm...

Immunotherapy-activated T cells recruit and skewlate-stage activated M1-like macrophages that are critical for therapeutic efficacy

Van Elsas et al. elucidated a critical role for M1-like macrophages (MΦs) in tumor control, and demonstrated that this population depended on intratumoral CD8+ T cells. These cells attracted MΦs via t...

Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination

Najibi et al. showed that compared to liquid bolus and common depot-based formulations, a mesoporous silica (MSP) nanoparticle formulation of model antigen induced stronger, more persistent dLN volume...

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

Everson and Hugo et al. evaluated safety and systemic immune responses in 23 patients with grade III-IV malignant glioma vaccinated with autologous tumor lysate-pulsed dendritic cells (ATL-DC) plus or...

Previous Digests

TMEs show night and day differences in accordance with circadian rhythms

May 15, 2024

Circadian rhythms allow organisms to operate on 24-hour cycles and coordinate periods of activity and rest in response to light and dark. These oscillations, controlled by both internal and external “clocks”, have also been shown to impact various aspects...

PGE(2) sabotages TIL expansion and effector differentiation

May 8, 2024

The bioactive lipid prostaglandin E2 (PGE2) is often detected in the tumor microenvironment (TME), and has been shown to play a role in immune escape and cancer progression. Two recent studies published in Nature assessed the effects of PGE...

Targeting IL-2 to CD8+ T cells enhances its benefits while reducing its risks

May 1, 2024

IL-2 is one of the earliest immunotherapeutic agents to induce complete responses in patients with cancer, but its use has been limited by its toxicity and the need for frequent administration. In order to capitalize on the desirable effects...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.